At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADMA ADMA Biologics
Trading 04-09 11:45:33 EDT
10.05
+0.22
+2.19%
High10.15Low9.60Vol1.17M
Open9.67D1 Closing9.83Amplitude5.60%
Mkt Cap2.39BTradable Cap2.35BTotal Shares238.00M
T/O11.59MT/O Rate0.50%Tradable Shares233.86M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

A Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations
Simply Wall St.  ·  16:25
A Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations
Assessing ADMA Biologics (ADMA) Valuation After Rebuttal To Short Seller Allegations
Simply Wall St.  ·  03-31
Assessing ADMA Biologics (ADMA) Valuation After Rebuttal To Short Seller Allegations
BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar
Reuters  ·  03-30
BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar
BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike
Reuters  ·  03-30
BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike
BUZZ-U.S. STOCKS ON THE MOVE-Energy shares, miners, Sysco
Reuters  ·  03-30
BUZZ-U.S. STOCKS ON THE MOVE-Energy shares, miners, Sysco
BUZZ-Law firm probes short-seller claims at ADMA Biologics; shares up
Reuters  ·  03-30
BUZZ-Law firm probes short-seller claims at ADMA Biologics; shares up
BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Reuters  ·  03-27
BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Adma Biologics call volume above normal and directionally bullish
TIPRANKS  ·  03-27
Adma Biologics call volume above normal and directionally bullish
Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Higher On Friday
Benzinga  ·  03-27
Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Higher On Friday
BUZZ-ADMA Biologics rises after rejecting short-seller's claims
Reuters  ·  03-27
BUZZ-ADMA Biologics rises after rejecting short-seller's claims
ADMA Biologics Issues Rebuttal to Short-Seller Allegations
TIPRANKS  ·  03-27
ADMA Biologics Issues Rebuttal to Short-Seller Allegations
Adma Biologics responds to short seller report by Culper Research
TIPRANKS  ·  03-27
Adma Biologics responds to short seller report by Culper Research
ADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026
Reuters  ·  03-27
ADMA Biologics refutes Culper Research allegations; ASCENIV distributor inventory averages 128 and 90 days on hand as of Jan. 5, 2026 and Mar. 22, 2026
ADMA Biologics Inc: Short Report Misrepresents and Conflates Asceniv's Utility and Competitive Positioning in Ivig Market
THOMSON REUTERS  ·  03-27
ADMA Biologics Inc: Short Report Misrepresents and Conflates Asceniv's Utility and Competitive Positioning in Ivig Market
ADMA Biologics : Refutes Key Allegations to Alleviate Confusion in Marketplace Concerning Company's Business Practices and Operations
THOMSON REUTERS  ·  03-27
ADMA Biologics : Refutes Key Allegations to Alleviate Confusion in Marketplace Concerning Company's Business Practices and Operations
ADMA Biologics : as a Late Line Therapy for Patients Who Have Failed Standard Ig, Asceniv Is in a Different Category and Commands Premium Pricing
THOMSON REUTERS  ·  03-27
ADMA Biologics : as a Late Line Therapy for Patients Who Have Failed Standard Ig, Asceniv Is in a Different Category and Commands Premium Pricing
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
GlobeNewswire  ·  03-27
ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
Why Are Shares Of ADMA Biologics Falling Today?
Benzinga  ·  03-27
Why Are Shares Of ADMA Biologics Falling Today?
ADMA Biologics Cut to Neutral From Overweight by Cantor Fitzgerald
Dow Jones  ·  03-26
ADMA Biologics Cut to Neutral From Overweight by Cantor Fitzgerald
Adma Biologics says Culper report contains ‘inaccurate statements’
TIPRANKS  ·  03-26
Adma Biologics says Culper report contains ‘inaccurate statements’

Introduction

Company Name.
ADMA Biologics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Issue price:
--